Seres Therapeutics Inc. | Mutual Funds
Mutual Funds that own Seres Therapeutics Inc.
ARK Innovation ETF
2,128,638
5.22%
0
1.32%
09/05/2018
Federated Kaufmann Fund
1,300,000
3.19%
0
0.17%
06/29/2018
Fidelity Growth Company Fund
1,247,218
3.06%
115,107
0.02%
07/31/2018
Fidelity Select Biotechnology Portfolio
1,028,440
2.52%
0
0.1%
07/31/2018
ARK Genomic Revolution Multi Sector ETF
871,142
2.13%
4,864
2.48%
09/05/2018
Vanguard Total Stock Market Index Fund
542,839
1.33%
0
0%
07/31/2018
iShares Nasdaq Biotechnology ETF
467,186
1.14%
-6,111
0.04%
09/06/2018
iShares Russell 2000 ETF
465,075
1.13%
-249
0.01%
09/06/2018
Fidelity Series Growth Company Fund
434,983
1.07%
33,391
0.03%
07/31/2018
Federated Kaufmann Small Cap Fund
432,800
1.06%
0
0.24%
06/29/2018
| Address |
200 Sidney Street
Cambridge Massachusetts 02139
United States
|
|
Employees
|
- |
| Website |
http://www.serestherapeutics.com |
| Updated |
07/08/2019 |
| Seres Therapeutics, Inc. is a microbiome therapeutics platform company, which engages in the development of biological drugs. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. |
